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ABSTRACT 
CDK5R1 (cyclin-dependent kinase 5 regulatory subunit 1) encodes p35, the main activatory subunit 
of CDK5 (cyclin-dependent kinase 5). The p35/CDK5 active complex plays a fundamental role in 
brain development and functioning, but its deregulated activity has also been implicated in various 
neurodegenerative disorders, including Alzheimer's disease (AD).  
CDK5R1 displays a large and highly evolutionarily conserved 3’-untranslated region (3’-UTR), a 
fact that has suggested a role for this region in the post-transcriptional control of CDK5R1 
expression. Our group has recently demonstrated that two miRNAs, miR-103 and miR-107, 
regulate CDK5R1 expression and affect the levels of p35. MiR-103 and miR-107 belong to the 
miR-15/107 family, a group of evolutionarily conserved miRNAs highly expressed in human 
cerebral cortex.  
In this work we tested the hypothesis that other members of this group of miRNAs, in addition to 
miR-103 and miR-107, were able to modulate CDK5R1 expression. We provide evidence that 
several miRNAs belonging to the miR-15/107 family regulate p35 levels. BACE1 expression levels 
were also found to be modulated by different members of this family. Furthermore, overexpression 
of these miRNAs led to reduced APP phosphorylation levels at the CDK5 specific Thr668 residue. 
We also show that miR-15/107 miRNAs display reduced expression levels in hippocampus and 
temporal cortex, but not in cerebellum, of AD brains. Moreover, increased CDK5R1 mRNA levels 
were observed in AD hippocampus tissues.  
Our results suggest that the downregulation of the miR-15/107 family might have a role in the 
pathogenesis of Alzheimer’s disease by increasing the levels of CDK5R1/p35 and consequently 
enhancing CDK5 activity. 
 
Keywords: 
CDK5R1/p35; CDK5; miR-15/107; post-transcriptional regulation; Alzheimer’s disease 
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INTRODUCTION 
CDK5R1 (cyclin-dependent kinase 5 regulatory subunit 1) encodes p35, a protein required for the 
activation of the serine/threonine kinase CDK5 (cyclin-dependent kinase 5). Through the activation 
of CDK5, p35 plays a critical role in several physiological processes in both embryonic and adult 
brain, including neuron maintenance and migration, cytoskeletal dynamics, neurite outgrowth, 
synaptogenesis, synaptic plasticity, behavior and cognition [1]. In particular, the CDK5/p35 
complex is essential for proper radial migration of neurons during the development of the 
mammalian cortex. In fact, mice lacking Cdk5 or p35 display severe defects in the migration and 
positioning of neurons and axonal fiber tracts [2, 3].  
If conditions the p35/CDK5 complex is essential for the correct development and functioning of the 
central nervous system (CNS) under normal physiological, CDK5 deregulated activity under 
pathological conditions has been implicated in various neurodegenerative disorders, particularly 
Alzheimer's disease (AD). Alzheimer's disease is a disorder causing a severe and permanent 
impairment of multiple cognitive faculties [4] which is having a huge social and economic impact 
on families and society. The incidence rate of AD among people 65 years of age and older is 19.4 
and 15.0 per 1000 person-years in Europe and US, respectively, but the incidence rate increases 
almost exponentially with increasing senility until 85 years of age [5]. There are two types of the 
pathology: familial and sporadic AD. The first one is a genetic condition with early onset, inherited 
in an autosomal dominant manner, which is caused by mutations in APP (amyloid precursor 
protein), PSEN1 (presenilin 1) or PSEN2 (presenilin 2) gene [6]. The second one is a late-onset 
complex condition whose molecular mechanisms are still poorly understood; some evidence shows 
a modest family clustering and interplay of genetic and environmental factors. The major genetic 
risk factor for this sporadic form is the presence of the epsilon 4 allele in the APOE (apolipoprotein 
E) gene, but recent genome-wide association studies and next-generation sequencing studies have 
successfully identified additional common genetic variations associated with late-onset AD [6].  
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Two main pathological hallmarks characterize AD: extracellular senile plaques, formed by the 
fibrillary β-amyloid (Aβ), and neurofibrillary tangles (NFTs), composed of the microtubule-
associated protein Tau (encoded by the MAPT gene) in a hyperphosphorylated status [7]. CDK5 
deregulation has been suggested to have a major role in the onset of these two neuropathological 
hallmarks. Under different stress conditions, including Aβ exposure, the regulatory subunit p35 is 
cleaved by the calcium-dependent protease calpain, generating a C-terminal truncated protein, p25, 
that retains the ability to bind the kinase and causes CDK5 hyperactivation and mislocalization [8, 
9]. Noteworthy, mice overexpressing p25 show increased CDK5 activity and hyperphosphorylation 
of Tau and APP proteins [10, 11]. Furthermore, the silencing of CDK5 reduces the phosphorylation 
of Tau in primary neurons and brain of wild-type mice and reduces neurofibrillary tangles in AD 
transgenic mice, indicating the involvement of CDK5 in Tau hyperphosphorylation [12]. In 
addition, APP phosphorylation by hyperactivated CDK5 at Thr668 makes it more prone to Aβ 
formation and has been proposed to represent an early event in AD [13, 14].  
CDK5R1 (the gene encoding p35), displays a large and highly evolutionarily conserved 3’-
untranslated region (3’-UTR), which has suggested a role for this region in the post-transcriptional 
control of CDK5R1 expression [15]. 3’-UTRs are known to function as post-transcriptional cis-
regulatory elements that allow a precise spatio-temporal control of gene expression by modulating 
mRNA stability and translation efficiency through the binding of proteins and non-coding RNAs 
[16], notably miRNAs. MiRNAs are small regulatory RNAs with established roles in 
neurodevelopment, neuroplasticity, apoptosis, and other neurobiological processes [17, 18]. 
Accumulating evidence implicates miRNAs in the pathogenesis of neurodegenerative diseases, 
particularly AD [19-22]. 
Our group has recently demonstrated that two miRNAs, miR-103 and miR-107, regulate CDK5R1 
expression and affect the levels of p35 [23], suggesting that miRNA-mediated mechanisms may 
influence CDK5 activity and the phosphorylation of its substrates, notably APP and Tau proteins. 
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MiR-103 and miR-107 belong to the miR-15/107 family, a group of ten paralogous and 
evolutionarily conserved miRNAs sharing the identical AGCAGC ‘seed’ sequence and known to 
regulate the expression of genes involved in cell division, metabolism, stress response and 
angiogenesis [24]. The members of this family are highly expressed in human cerebral cortex [24, 
25]. Recent evidence supports the hypothesis that miRNAs belonging to the miR-15/107 group are 
involved in AD pathogenesis. Expression levels of miR-15a and miR-107 are significantly reduced 
in AD brains compared to control brain samples [26-29]. Changes in miR-15a and miR-16 levels 
have been shown to affect Tau phosphorylation in primary cortical neurons [28]. Moreover, miR-16 
directly targets APP [30] and miR-195 has been shown to regulate APP and BACE1 levels, as well 
as Aβ production [31, 32].  
Therefore, besides the well-known paradigm of p25 production by calpain leading to CDK5 
hyperactivity, other mechanisms might be evoked to explain CDK5 hyperactivation in AD, among 
them, the dysregulation of miRNAs that post-transcriptionally control CDK5R1 expression. 
Since the members of the miR-15/107 family share an identical ‘seed’ sequence, in this work we 
tested the hypothesis that other members of this group of miRNAs, in addition to miR-103 and 
miR-107, were able to modulate CDK5R1 expression. We provide evidence that the main and most 
conserved members of the miR-15/107 group regulate p35 levels. BACE1 expression levels were 
also found to be modulated by several members of this family. Furthermore, overexpression of 
these miRNAs led to reduced APP phosphorylation levels at the CDK5 specific Thr668 residue 
without affecting CDK5 cellular levels. We also show that miR-15/107 miRNAs display reduced 
expression levels in the hippocampus and temporal cortex, but not in the cerebellum, of AD brains 
compared to control samples. Moreover, increased CDK5R1 mRNA levels were observed in AD 
hippocampi, compared to controls. Our results suggest that increased levels of CDK5R1/p35 and 
consequent enhanced CDK5 activity caused by downregulation of the miR-15/107 family of 
miRNAs might be a further contributor to the pathogenesis of Alzheimer’s disease. 
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MATERIALS AND METHODS 
Cell cultures 
Human neuroblastoma SK-N-BE (2) cells (ATCC code CRL-271) were cultured in RPMI-1640 
medium with 10% fetal bovine serum (FBS), 100 U/ml penicillin-streptomycin, 0.01 mM L-
glutamine, sodium pyruvate 11 g/l and glucose 4.5 g/l. Human embryonic kidney HEK-293 cells 
(ATCC code CRL-1573) were maintained in DMEM medium with 10% FBS, 100 U/ml penicillin-
streptomycin and 0.01 mM L-glutamine. Cultures were maintained at 37°C in a 5% CO2 incubator. 
 
Brain tissues 
Post-mortem frozen brain tissue samples of AD patients (n=12, age=83 ± 8, m/f (%): 60/40) and 
age- and sex-matched non-demented individuals (n=12) were obtained from MRC London 
Neurodegenerative Diseases Brain Bank (King’s College London), Newcastle Brain Tissue 
Resource (Newcastle University) and South West Dementia Brain Bank (University of Bristol).  
Tissue blocks were from hippocampus, anterior temporal cortex and cerebellum, which are 
differently affected by AD pathology. All samples had a post-mortem interval (PMI) < 25 hours 
(mean=10, median=10.5). The approval of the Ethics Committee of the University of Milan was 
obtained for the use of post-mortem tissues for research purposes (19.05.2011). 
 
Pre-miRs and LNA anti-miRs transfection 
The dsRNA miRNA precursors (pre-miRs) that mimic endogenous mature miRNAs (AM 17100: 
PM 10632 hsa-mir-103a-3p; PM 10339 hsa-mir-16-5p; PM 10235 hsa-mir-15a-5p), and the PremiR 
miRNA Precursor Molecules-Negative Control#1 (AM 17110) were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). LNA anti-miR oligonucleotides (mircury LNA inhibitors) were 
purchased from Exiqon (Vedbæk, Denmark). Each molecule inhibits one or two miRNAs: anti-
miR-103/7 (hsa-miR-103 miRCURY LNATM microRNA family, EX450028), anti-miR-15a/16, 
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anti-miR-15b, anti-miR-195 (all three oligonucleotides included in hsa-miR-15 miRCURY LNATM 
microRNA family, EX450022). Single LNA anti-miRs were used at 5 or 25 nM concentration. 
LNA mixes were made using equal amounts of each anti-miR, to get a total concentration of 5 or 25 
nM. 125x103 SK-N-BE cells and 100x103 HEK-293 cells were seeded in 12-well plates, in order to 
extract total RNA (double quantity of cells was used in 6-well plates to extract proteins). The cells 
were transfected 24 h after seeding with pre-miRs (100 nM) or LNA anti-miR molecules (5 or 25 
nM), using Lipofectamine 2000 (Thermo Fisher Scientific) transfection reagent according to the 
manufacturer’s instruction. Cell extracts were prepared for analysis 48 h after the transfection. 
 
Real-time PCR 
Total RNA from transfected/nontransfected cells and from brain tissues (100 mg of each sample 
tissue were used) were isolated using TRIzol reagent (Thermo Fisher Scientific), according to the 
manufacturer’s instructions. Concentration and purity of RNA were measured using the Nanodrop 
spectrophotometer (Thermo Fisher Scientific). All RNA samples had an A260/A280 value of 1.8-
2.1. 
For the quantitative analysis of mature miRNAs, a two-step Taq-Man real-time PCR assay was 
performed, using primers and probes obtained from Thermo Fisher Scientific. cDNA was 
synthesized from total RNA (50 ng) in 15 μl reactions, using reverse transcriptase and the stem–
loop primer for miR-15a (ID000389), miR-15b (ID000390),  miR-16 (ID000391), miR-103 
(ID000439), miR-107 (ID000443), miR-195 (ID000494), miR-34a (ID000426) or RNU6B 
(endogenous control as recommended by Thermo Fisher Scientific; ID001093) contained in the 
TaqMan MicroRNA Reverse Transcription kit (Thermo Fisher Scientific). The reverse transcriptase 
reaction was performed by incubating the samples at 16°C for 30 min, 42°C for 30 min, and 85°C 
for 5 min. The PCR reaction (20 μl) contained 1.3 μl of reverse transcriptase product, 10 μl of Taq-
Man Universal PCR Master Mix, and 1 μl of the appropriate TaqMan MicroRNA Assay (20X) 
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containing primers and probes for the miR of interest. The PCR mixtures were incubated at 95 °C 
for 10 min, and this was followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. The expression 
of miRs was based on the ΔCT method, using RNU6B as an endogenous control. 
For the measurement of CDK5R1 and BACE1 mRNA, cDNA was synthesized from total RNA (1 
μg) in 20 μl reactions using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific). Real-Time PCR was performed using the SYBR Green PCR Master mixture (Promega, 
Madison, WI, USA) and the following primers: CDK5R1 fw: TGAGCGGGTCTAGTGGAAAG, 
CDK5R1 rev: AGCAGCAGACAAGGGGGTAG, BACE1 fw: GCAGGGCTACTACGTGGAGA; 
BACE1 rev: GTATCCACCAGGATGTTGAGC; CYC1 fw: TAGAGTTTGACGATGGCACCC, 
CYC1 rev: CGTTTTCGATGGTCGTGCTC; EIF4A2 fw: GGTCAGGGTCAAGTCGTGTT, 
EIF4A2 rev: CCCCCTCTGCCAATTCTGTG; SYP fw: CTTCGCCATCTTCGCCTTTG, SYP rev: 
TACACTTGGTGCAGCCTGAAG; GAPDH fw: TGCACCACCAACTGCTTAGC, GAPDH rev: 
GGCATGGACTGTGGTCATGAG. The PCR reactions (20 μl) were prepared with 2X SYBR 
Green mix containing 1 μl of reverse transcriptase product and 0.2 μl of each primer. The PCR 
mixtures were incubated at 95°C for 3 min, followed by 40 cycles of 95°C for 10 s, 60°C for 20 s 
and 72°C for 10 s. The expression of CDK5R1 and BACE1 was based on the ΔΔCT method. The 
house-keeping gene GAPDH was used as internal control in pre-miR and anti-miR transfection 
experiments, while the house-keeping genes CYC1 and EIF4A2, and the neuronal marker SYP 
were used to normalize gene expression levels in brain tissues. All PCRs were performed in 
triplicate using an iQ5 Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA). 
 
Western blotting 
SK-N-BE and HEK-293 cells were homogenized in lysis buffer (150 mM NaCl, 20 mM Tris-HCl, 
pH 7.4, 1% Triton X-100, protease inhibitor mixture). Samples were centrifuged at 12,000 g for 15 
min at 4 °C and supernatants were collected.  
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Western blot assay was performed under standard conditions. In brief, equal amounts of proteins 
were analyzed by 12% SDS-PAGE at 100 V for 90 min and blotted onto nitrocellulose membrane 
Hybond-enhanced chemiluminescence (ECL; Amersham Biosciences, Buckinghamshire, UK) in a 
Bio-Rad Trans-blot apparatus at 350 mA for 3 hours. The blots were probed with anti-p35 (C-19, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-BACE1 (D10E5, Cell Signaling, Beverly, 
MA), anti-CDK5 antibody (C-8, Santa Cruz Biotechnology), anti-pAPP (Thr668) (Cell Signaling, 
Danvers, CA, USA), anti-APP (Millipore, Billerica, MA, USA) and anti GAPDH (Novus 
biologicals, Littleton, CO, USA) antibodies followed by an alkaline phosphatase-conjugated IgG 
secondary antibody. Blots were processed by an ECL Plus detection kit as instructed by the supplier 
(Amersham Biosciences). All experiments were performed at least three times, and the quantization 
was made using the ImageJ program (National Institute of Health, Bethesda, MD, USA). 
 
3’-UTR and “miR-sensor” constructs 
The Renilla luciferase pGL4.71P construct (Promega) containing the CDK5R1 3’-UTR was 
previously described [23]. For transfection efficiency normalization the pGL3 firefly luciferase 
plasmid (Promega) was used.  
For the generation of “miR-sensor” constructs, oligonucleotide pairs were designed to contain the 
desired mature miRNA sequence and, when annealed, overhangs complementary to those generated 
by XbaI digestion (Table S1). Once ligated into the pmirGLO Vector (Promega) the result is a 
region perfectly complementary to the mature miRNA in the 3’-UTR of the hRluc reporter gene. 
Both oligonucleotides were diluted to 1 µg/µl and 2 µl of each oligonucleotide were combined with 
46 µl of Oligo Annealing Buffer, heated at 90°C for 3 minutes, and then transferred to a 37°C water 
bath for 15 minutes. Annealed oligonucleotides were diluted 1:10 in nuclease-free water to a final 
concentration of 4 ng/µl per oligonucleotide and 4 ng of annealed oligonucleotides were ligated 
with 50 ng of XbaI linearized vector using a standard ligation protocol. The correct orientation of 
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the insertion was verified by direct sequencing. This method was used to generate “sensor” 
luciferase constructs specific for each member of the miR-15/107 family (sensor-103, sensor-107, 
sensor-15a, sensor-15b, sensor-16 and sensor-195) and miR-34a (sensor-34a). The sensor-34a was 
chosen as a negative control because miR-34a is not expressed in SK-N-BE cells [23]. The same 
sensor constructs with a 4-bases mutation inside the seed sequence were produced by direct 
mutagenesis, using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) 
with specific oligonucleotides (Table S1), according to the protocol provided with the kit. 
 
Luciferase assay 
For transient transfection of SK-N-BE cells with pre-miRs and the luciferase construct containing 
the entire human CDK5R1 3’-UTR, 125x103 cells were seeded in 12-well plates and then 
transfected with 100 nM pre-miRs, 24 h after seeding, and with the luciferase reporter construct 
(150 ng), 48 h after seeding, using Lipofectamine 2000 transfection reagent according to the 
manufacturer’s instruction. To normalize the value of Renilla luciferase activity for transfection 
efficiency and cell viability after transfection, we cotransfected the pGL3-Promoter Firefly 
luciferase reporter gene (150 ng). 72 h after seeding, cells were washed with PBS and lysed with 
passive lysis buffer (Promega), the Renilla and Firefly luciferase activities were measured using the 
Dual-Glo Luciferase Assay System (Promega) in a single channel luminometer. Each experiment 
was performed at least three times. 
For transient transfection of SK-N-BE with wild type and mutated “sensor” constructs, 125x103 
cells were seeded in 12-well plates and then transfected with 150 ng of the specific sensor construct, 
24 h after seeding using Lipofectamine 2000 transfection reagent. pimiRGLO contains both Renilla 
and Firefly reporter genes. 48 h after seeding, the luciferase activity was determined as described 
above. 
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Finally, 125x103 SK-N-BE cells were seeded in 12-well plates and then transfected with 150 ng of 
the specific wt “sensor” construct only, or cotransfected with 5 nM of the corresponding LNA anti-
miR molecule. 48 h after anti-miR transfection and 24 h after “sensor” constructs transfection, 
cellular lysates were subjected to luciferase assays, as described above.   
 
Statistical analysis 
Each experiment was carried out three times, at least. Histograms represent the mean values and 
bars indicate the standard deviation of the mean. The box plots show median, 25 and 75 percentile 
values and whiskers to the minimum and maximum value. The statistical significance of the results 
was determined using Student’s t-test, with data considered significant when p < 0.05. The degree 
of linear relationship between miRNA and gene expression levels was calculated using Pearson’s 
correlation coefficient (r value) using the mean values of three experiments. The p value is 
calculated from an extra sum-of-squares F test. 
 
RESULTS 
miR-15/107 family modulates CDK5R1 expression  
We recently demonstrated that two miRNAs, miR-103 and miR-107, both belonging to the miR-
15/107 family, regulate CDK5R1 expression through the binding to its 3’-UTR and affect the levels 
of p35 [23]. To verify whether the CDK5R1 mRNA and p35 cellular levels are also regulated by 
other members of the miR-15/107 group, we transiently transfected SK-N-BE and HEK-293 cells 
with the precursors of other two representative members of the miR-15/107 family: miR-15a and 
miR-16.  
Total mRNA was extracted from SK-N-BE and HEK-293 cells 48 hours after transfection with 100 
nM pre-miR-15a, pre-miR-16, pre-miR-103 (as a positive control) or a scramble control. qRT-PCR 
analysis showed a decrease in CDK5R1 transcript levels after transfection with the miR-103 
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precursor in both cell lines, as expected [23], and after transfection with the other two precursors 
only in HEK-293 cells (Fig. 1a). 48 h after pre-miRNA transfection, a significant reduction of the 
p35 levels was also observed by Western blot analysis in both cell lines, compared to the scramble 
control (Fig. 1b).  
To investigate whether miR-15/107 miRNAs can act in a direct or indirect manner on CDK5R1 3’-
UTR, luciferase assays were performed. A luciferase construct containing the entire human 
CDK5R1 3’-UTR [23] and a pGL3 firefly luciferase plasmid were co-transfected with 100 nM pre-
miR-103, pre-miR-15a or pre-miR-16 in SK-N-BE cells and the luciferase activity was measured by 
a dual luciferase assay. The luciferase activity decreased following the co-transfection with all three 
precursors compared to the untransfected cells or to the cells transfected with pre-miR-34a, which 
has no target sites in CDK5R1 3’-UTR (Fig. 1c), demonstrating a direct action of these miRNAs on 
CDK5R1 3’-UTR.  
To further analyze the effect of miR-15/107 family on CDK5R1 expression, we used locked nucleic 
acid (LNA) antisense oligonucleotides with perfect sequence complementarity to the main members 
of the miR-15/107 group to inhibit their endogenous activity. qRT-PCR on mature miRNAs is not a 
reliable method for measuring the level of miRNA knock-down by miRNA inhibitors, as they do 
not degrade their targets but rather form stable complexes with their targets causing an 
accumulation of the miRNA due to reduced turnover. For this reason, to test the efficacy of the 
LNA oligonucleotides in inhibiting endogenous miR-15/107 activity, we decided to generate 
“sensor” luciferase constructs by cloning a sequence perfectly complementary to the mature 
miRNA of interest downstream the firefly luciferase of the pmiR-GLO plasmid. The binding of the 
endogenous miRNA to the corresponding target sequence is expected to result in decreased 
luciferase activity, due to the repressive action of the miRNA. Indeed, we measured a a significant 
luciferase activity reduction in SK-N-BE cells for every transfected pmiR-GLO-sensor, compared 
to the empty pmiR-GLO control vector, indicating that all the miRNAs of the miR-15/107 family 
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tested have a significant endogenous activity in this cell line (Fig. S1a). On the contrary, no 
reduction in luciferase activity was observed for the miR-34a sensor, as expected, given that miR-
34a is not expressed in SK-N-BE cells [23]. To ensure the specificity of miRNA binding to the 
sensors, we generated sensor constructs mutated in the seed region. The luciferase activity of the 
mutant constructs was increased in all cases (Fig. S1b).  
To verify the efficacy of miRNA inhibition by antisense LNA molecules, we co-transfected each 
sensor with 5 nM of the corresponding LNA miRNA inhibitor (anti-miR) in SK-N-BE cells. In each 
case, we observed a significant increase of the luciferase activity (Fig. S1c), indicating an effective 
reduction of the miRNA repressive activity caused by the inhibitors. 
Following the transfection of the miR-15/107 LNA inhibitors in SK-N-BE and HEK-293 cell lines, 
we extracted total RNA and proteins and performed qRT-PCR and Western blot experiments, to 
assess the levels of CDK5R1 mRNA and p35 after the treatment. In SK-N-BE cells, significantly 
augmented CDK5R1 mRNA levels were measured by qRT-PCR after the transfection with 5 nM 
anti-miR-103/107 and with 25 nM anti-miR-103/107, anti-miR-15a/16 and a mix including all the 
inhibitors (anti-miR-103/7-15a/16-15b-195), compared to an equal dose of control anti-miR (anti-
miR-C-) (Fig. 2a). In HEK-293 cells, CDK5R1 transcript levels significantly increased following 
the transfection of 5 nM anti-miR-103/107, anti-miR-15a/16, a mix containing all the inhibitors 
except anti-miR-103/107 (anti-miR-15a/16-15b-195) and the mix containing all the inhibitors. At 
25 nM dose, a significant increase of CDK5R1 mRNA levels was observed after the transfection 
with all single anti-miRs and mixes (Fig. 2a). Western blot analysis showed that the transfection of 
5 nM anti-miR-103/107, anti-miR-15a/16, anti-miR-15b or anti-miR-195, as well as of the 
inhibitors mixes lead to a significant increase (up to two-fold) of p35 levels, compared to the 
control, in both cell lines (Fig. 2b). 
Taken together, these data support the hypothesis that several members of the miR-15/107 group of 
miRNAs regulate CDK5R1 expression. 
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miR-15/107 family modulates BACE1 expression 
BACE1 is a known target of miR-107 and miR-195 which is involved in the pathogenesis of AD 
[27, 31]. We tested the hypothesis that other members of the miR-15/107 family can regulate 
BACE1 expression. A reduction of the levels of BACE1 was observed by Western blot analysis 
following the transfection of SK-N-BE cells with 100 nM pre-miR-15a, pre-miR-16 and pre-miR-
103, compared to the scramble control (Fig. 3a). Moreover, BACE1 protein levels increased after 
the transfection of the same cell line with 5 nM anti-miR-103/107, anti-miR-15a/16, anti-miR-15b 
or anti-miR-195 inhibitors and inhibitors mixes (Fig. 3b). These experiments demonstrated that, in 
addition to miR-107 and miR-195, also other members of the miR-15/107 group of miRNAs 
regulate BACE1 expression. 
 
miR-15/107 miRNAs do not influence CDK5 expression but its kinase activity 
We also wanted to investigate whether miR-15/107 miRNAs can affect the levels of the CDK5 
kinase. To test this hypothesis we transfected SK-N-BE cells with 100 nM of the miR-15/107 
precursors (pre-miR-15a, pre-miR-16 and pre-miR-103), extracted total proteins and measured 
CDK5 levels by Western blot. We observed no change in CDK5 levels after the treatments, 
compared to the scramble control (Fig. 4a). 
We then tested the effect of the miR-15/107 family on CDK5 activity by studying one of the known 
targets of CDK5: the amyloid precursor protein (APP), which is specifically phosphorylated by 
CDK5 at the threonine 668 residue [13]. We transfected SK-N-BE cells with the miR-15/107 
precursors and measured the levels of pAPP-Thr668 and total APP in Western blot analysis. A 
reduction of APP phosphorylation levels, measured as pAPP-Thr668:APP ratio, was observed after 
48 h treatment with 100 nM pre-miR-103 and pre-miR-15a (Fig. 4b), suggesting that miRNAs 
belonging to the miR-15/107 group can control CDK5 activity acting on the levels of the regulatory 
subunit p35 but leaving unchanged the levels of the kinase. 
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miR-15/107 family is downregulated in AD temporal cortex and hippocampus 
CDK5 deregulation has been suggested to have a major role in the onset of Alzheimer’s disease 
[14]. While p35 cleavage by calpain, to generate the truncated p25 form, leading to CDK5 
hyperactivity, has been proposed since a long time as a possible pathogenic mechanism related to 
AD [8, 9], CDK5 aberrant activity could also be caused, at least partially, by altered miRNA-
mediated regulation of its activator p35. To evaluate whether an altered expression of miR-15/107 
miRNAs is associated to AD, we measured their levels by qRT-PCR in post-mortem tissue samples 
from the temporal cortex, hippocampus and cerebellum of 12 AD patients and 12 age-matched 
healthy controls. These experiments showed that the most expressed miRNA is miR-16, followed 
by miR-195 and miR-103, in both AD patients and control derived tissue samples (Fig. S2). A 
significant reduction of miRNA expression levels was observed in the temporal cortex and 
hippocampus of AD patients, compared to controls, for all analyzed miR-15/107 miRNAs, except 
miR-15a. On the contrary, no statistically significant difference in miRNA levels between patients 
and controls was detected in the cerebellum (Fig. 5).  
 
CDK5R1 mRNA levels are increased in AD hippocampus 
Since we observed reduced levels of members of the miR-15/107 family in AD brains, we also 
performed qRT-PCR experiments in the same tissue samples, to verify if a corresponding CDK5R1 
mRNA upregulation could be detected. The mRNA levels of BACE1, which has been reported to 
be upregulated in AD [27], were also measured. The transcript levels of the two genes were 
normalized against the median expression levels of the CYC1 (Cytochrome c1) and EIF4A2 
(eukaryotic translation initiation factor 4A, isoform 2) housekeeping genes, as suggested by Penna 
and colleagues [33], as well as against the levels of the neuronal marker SYP, in order to normalize 
gene expression taking into account the neuronal population only [34]. 
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Our qRT-PCR experiments showed no significant differences in CDK5R1 and BACE1 mRNA 
levels between AD and control tissues when normalized to the CYC1 and EIF4A2 housekeeping 
genes in temporal cortex and hippocampus (Fig. 6). Instead, reduced transcript levels were detected 
for both genes in the cerebellum of AD patients, compared to controls. On the contrary, when 
normalizing to SYP expression, we evidenced an increase of CDK5R1 mRNA levels in the 
hippocampus of AD samples, compared to the controls (Fig. 6); BACE1 mRNA levels were also 
increased in AD hippocampus, even if the data were slightly above the statistical significance (p= 
0.078). A trend of increased levels were also observed in temporal cortex for both genes, but the 
results were not statistically significant (CDK5R1, p= 0.19; BACE1, p= 0.23). Reduced CDK5R1 
and BACE1 mRNA levels were still displayed in AD cerebellum tissues. Moreover, the expression 
levels of CDK5R1 were significantly higher in temporal cortex and hippocampus compared to 
cerebellum in AD patients but not in control individuals (Fig. S3). BACE1 levels were comparable 
in AD tissues while they were significantly reduced in temporal cortex and hippocampus compared 
to cerebellum in control tissue samples. These findings suggest that an altered expression of 
CDK5R1 and BACE1 may specifically occur in the neuronal component of AD tissues. We also 
calculated the Pearson’s correlation between the expression levels of miR-15/107 miRNAs and 
CDK5R1 and BACE1 genes (normalized on SYP). We found a significant inverse correlation of 
expression between every miRNA (except miR-15a) and CDK5R1 in hippocampus samples (Fig. 
7). We also observed an inverse correlation between miRNA and CDK5R1 expression levels in 
temporal cortex and cerebellum, as well as between miRNA and BACE1 expression levels in all 
three tissues, but these data did not reach the statistical significance (data not shown). 
Overall, these data suggest a role of the miR-15/107 family of miRNAs in the pathogenesis of AD 
through upregulation of CDK5R1 and BACE1. 
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DISCUSSION 
In the last two decades, post-transcriptional regulation has decisively emerged as an additional level 
of gene expression control whose importance is, at least, equal to that exerted by transcriptional 
regulation, providing the cell an efficient way to induce rapid changes in protein synthesis without 
the need for transcriptional activation and subsequent mRNA processing steps. Importantly, it is 
now recognized that alterations of post-transcriptional mechanisms can contribute to a variety of 
disorders in humans [35]. MicroRNAs (miRNAs) are small, 21-23 nt-long, non-coding RNAs with 
a key post-transcriptional regulatory function. These small RNAs play a role in neurodevelopment, 
neuroplasticity, apoptosis, and other fundamental neurobiological processes [17, 18], acting as 
negative regulators of the expression of hundreds of target genes, either by triggering mRNA 
degradation or by blocking translation [36]. It is therefore not surprising that dysregulation of 
miRNAs has been recently implicated in neurodegenerative disorders [19, 21], including 
Alzheimer’s disease (AD) [20, 22]. Altered expression of several miRNAs has been found in AD 
brains, a relevant number of which have been involved in the regulation of genes with a key role in 
AD pathogenesis, notably APP and BACE1 (reviewed in [22]). In particular, different members of 
the miR-15/107 group of miRNAs have been recently involved in AD pathogenesis in various 
ways, including alteration of APP, BACE1 and Cofilin levels, Aβ production, and Tau 
phosphorylation levels [26-32, 37]. We previously demonstrated that two miRNAs belonging to this 
family, miR-103 and miR-107 regulate CDK5R1 expression, thereby affecting the levels of the 
encoded protein, p35 [23]. p35 represents the main activatory subunit of the CDK5 kinase, whose 
deregulation has been implicated in AD pathogenesis [10-14].  
The present work provides evidence that all the main and most conserved members of the miR-
15/107 group, not only miR-103 and miR-107, modulate CDK5R1 expression and p35 levels, 
through the binding to CDK5R1 3’-UTR, as showed by luciferase assays. The expression of another 
protein relevant to AD, BACE1, was also found to be regulated by several members of this family. 
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Moreover, APP phosphorylation at threonin 668, a residue specifically phosphorylated by CDK5 
[13], was significantly reduced upon overexpression of different miR-15/107 miRNAs, suggesting 
that CDK5 activity can be modulated by the cellular levels of these miRNAs. We also found that 
miR-15/107 miRNAs are downregulated in the hippocampus and temporal cortex, but not in 
cerebellum, of AD patients and that CDK5R1 mRNA levels are upregulated in the AD 
hippocampus. Importantly, an inverse correlation between miR-15/107 miRNAs and CDK5R1 
mRNA levels was detected in hippocampus of AD patients.  
In our study, we analyzed the main and most conserved miRNAs of the miR-15/107 group, i.e. 
miR-103, miR-107, miR-15a, miR-15b, miR-16 and miR-195, which were also found to be the 
most highly expressed in human brain by microarray experiments, while the remaining members of 
the family - miR-497, miR-503, miR-424 and miR-646 - showed low expression levels [24]. 
However, miR-497 was recently found to be highly expressed in brain using another platform for 
expression analysis, deep sequencing RNA-seq [25]. Therefore, we cannot exclude a relevant role 
in the regulation of CDK5R1 expression also for this member of the family. 
Our findings are in accordance with evidence regarding one member of the miR-15/107 family, 
miR-195, which was recently shown to bind CDK5R1 3’-UTR, thereby inhibiting p35 expression 
and reducing CDK5 activity and Tau phosphorylation in rat hippocampi and cultured neurons [38].  
Despite CDK5 3’-UTR does not contain any miR-15/107 predicted binding sites, an indirect effect 
on CDK5 levels by regulation of other targets which are in turn able to influence CDK5 cellular 
abundance cannot be excluded. Our experiments showed that CDK5 levels are not affected by miR-
15/107 overexpression, suggesting that these miRNAs can control CDK5 activity exclusively 
modulating the levels of the regulatory subunit p35. This evidence is also supported by the study of 
Sun and collaborators who did not observe changes in CDK5 levels after miR-195 knockdown or 
overexpression in rat hippocampi and neurons [38]. 
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It is worth noting that, in our set of data, the overexpression of miR-16 does not reduce BACE1 
levels as efficiently as the other miRNAs. This is at variance with what recently found by Parsi and 
colleagues, who reported that miR-16 is the most efficient in repressing human BACE1 protein 
among its family members. On the other hand, differently from our results, their data did not 
support the action of miR-103 on BACE1 levels [39]. These discrepancies may be ascribed to the 
different cell lines and/or to the different concentrations of miRNA precursors/mimics used in the 
two studies. However, miR-16 reduces APP phosphorylation to a level similar to that of miR-103 
and miR-15a, albeit lacking statistical significance due to slightly higher variability in the three 
replicates. This evidence is consistent with the ability of miR-16 to reduce p35 to levels comparable 
to that of the other two miRNAs.  
Our expression data confirm prior evidence of downmodulation of miR-15/107 miRNAs in AD 
brains [26-29]. In particular, we observed reduced expression levels in hippocampus and temporal 
cortex of AD patients for all analyzed miRNAs except miR-15a. These results on miR-15a are not 
consistent with those obtained by Hébert and colleagues [28], who observed miR-15a 
downregulation in AD brains. On the contrary, they did not detect a decrease of miR-195, as 
showed by our expression analysis. A bias due to the low sample size might be a possible 
explanation of these discrepancies. It is also interesting to note that we did not observe 
downmodulation of miR-15/107 miRNAs in AD cerebellum, which has been shown to be largely 
spared by the neurodegenerative process. 
The results obtained by our and other groups ultimately show that different genes (APP, BACE1, 
CDK5R1) and molecular processes (amyloidogenesis, APP and Tau phosphorylation) involved in 
the pathogenesis of Alzheimer’s disease are regulated by the miR-15/107 family of miRNAs, which 
is dysregulated in AD. Taken together, these findings point to these miRNAs as true “AD-miRs”, 
whose altered expression can simultaneously affect different AD-related pathways, contributing to 
trigger the neurodegenerative process. As such, the miR-15/107 family of miRNAs could constitute 
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an optimal target for the development of drugs that can simultaneously act on different pathways 
involved in AD neurodegeneration [39]. 
Interestingly, the miR-15/107 microRNA gene group was also showed to cause dysregulation of 
Granulin (GRN) [40, 41], a gene implicated in frontotemporal dementia (FTD) [42], suggesting a 
very broad involvement of this miRNA family in the pathogenesis of dementias.  
We recently demonstrated that, besides microRNAs, CDK5R1 3’-UTR is also bound by two 
different classes of RNA-binding proteins (RBPs), nELAVs (neuronal ELAV-like proteins) and 
hnRNPA2/B1, which showed an opposite effect on CDK5R1 transcript stability [43]. These 
findings highlight the complexity of the regulation of CDK5R1 expression at the post-
transcriptional level, where different trans-acting factors, both miRNAs and RNA-binding proteins, 
can contribute to the determination of p35 levels. It is worth noting that CDK5R1 3’-UTR is 
characterized by the presence of several AU-rich elements (ARE) [15], composed by a core 
sequence of AUUUA within a U-rich contest. Since both nELAVs, that are well-known ARE-
binding proteins, and miR-16, which contains the UAAAU complementary sequence, recognize 
these cis-regulatory elements, possible competition for binding to the same ARE sequences may be 
suggested. Moreover, given that, besides miR-15/107 miRNAs, both nELAVs and hnRNPA2/B1 
RBPs were also shown to display altered expression in AD brains [44, 45], we hypothesize that 
deregulation of post-transcriptional control of CDK5R1 expression might constitute a 
pathomechanism in Alzheimer’s disease. 
Collectively, our data support a relevant role of the miR-15/107 group of miRNAs in the 
pathogenesis of AD, affecting the levels of genes with a key involvement in the molecular events 
leading to neurodegeneration, such as CDK5R1 and BACE1. Our findings ultimately confirm that 
the miR-15/107 family is a promising candidate pharmacological target for Alzheimer’s disease 
drug development. 
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FIGURE LEGENDS 
 
Fig. 1 
miR-15/107 precursors reduce p35 levels. a SK-N-BE and HEK-293 cells were treated with 100 
nM pre-miR-103, pre-miR-15a, pre-miR16 or a scramble control. After 48 h total RNA was 
extracted and the levels of CDK5R1 mRNA were measured with qRT-PCR and normalized on the 
housekeeping GAPDH gene. Results are compared with the cells treated with the scramble control. 
n = 5, mean ± s.d.  b SK-N-BE or HEK-293 cells were treated as in A and western blot on p35 and 
GAPDH was performed on protein lysates. n = 5, mean ± s.d. c A pGL4.11 firefly luciferase 
construct containing the entire human CDK5R1 3’-UTR and a pGL3 Renilla luciferase plasmid as 
normaliser (Moncini et al., 2011) were cotransfected with 100 nM miR-103/107, miR-15a and miR-
16 precursors in SK-N-BE cells and the luciferase activity was measured by a dual luciferase assay 
after 72 h. Results are represented as firefly/Renilla luciferase activity. n = 5, mean ± s.d., * p<0.05;  
** p<0.01, Student’s t-test 
 
Fig. 2 
miR-15/107 inhibition increases p35 levels. a SK-N-BE and HEK-293 cells were treated with 5 nM 
(dark grey) or 25 nM (light grey) anti-miR-C- scramble control, anti-miR-103/7, anti-miR-15a/16, 
anti-miR-15b, anti-miR-195 or a combination of anti-miR. After 48 h total RNA was extracted and 
the levels of CDK5R1 mRNA were measured with qRT-PCR and normalized on the housekeeping 
GAPDH gene. Results are compared with the cells treated with the scramble control. n = x, mean ± 
s.d. b SK-N-BE or HEK-293 cells were treated with 25 nM anti-miR as in A and western blot on 
p35 and GAPDH was performed on protein lysates. n = 5, mean ± s.d. , * p<0.05; ** p<0.01, 
Student’s t-test 
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Fig. 3 
miR-15/107 regulate BACE1 levels. a SK-N-BE cells were treated with 100 nM pre-miR-103, pre-
miR-15a, pre-miR16 or a scramble control. After 48 h total western blot on BACE1 and GAPDH 
was performed on protein lysates. n = 5, mean ± s.d. b SK-N-BE cells were treated with 5 nM anti-
miR-C- scramble control, anti-miR-103/7, anti-miR-15a/16, anti-miR-15b, anti-miR-195 or a 
combination of anti-miR. After 48 h total western blot on BACE1 and GAPDH was performed on 
protein lysates. n = 5, mean ± s.d.. * p<0.05 ** p<0.01, Student’s t-test 
 
Fig. 4 
miR-15/107 effects on CDK5 level and activity. a SK-N-BE cells were treated with 100 nM pre-
miR-103, pre-miR-15a, pre-miR16 or a scramble control. After 48 h total western blot on CDK5 
and GAPDH was performed on protein lysates. n = 3, mean ± s.d. b SK-N-BE cells were treated 
with 100 nM pre-miR-103, pre-miR-15a, pre-miR16 or a scramble control. After 48 h total western 
blot on pAPP-Thr668 and total APP was performed on protein lysates. n = 3, mean ± s.d. , * 
p<0.05, Student’s t-test 
 
Fig. 5 
Comparison between the levels of miR-15/107 miRNAs expression in AD and control brain tissues. 
Box-plot of the levels of miRNAs expression in three different brain areas (temporal cortex, 
hippocampus and cerebellum) of AD patients and controls. Dark horizontal lines represent the 
median, with the box representing the 25th and 75th percentiles, the whiskers the 5th and 95th 
percentiles. For each miR, the average of control values was set to 1 and all values were calculated 
relatively. * p<0.05 ** p<0.01, Student’s t-test 
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Fig. 6 
Comparison between the levels of CDK5R1 and BACE1 expression in AD and control brain 
tissues. Box-plot of the levels of CDK5R1 and BACE1 mRNAs expression in three different brain 
areas (temporal cortex, hippocampus and cerebellum) of AD patients and controls. Results are 
shown normalized on housekeeping genes EIF4A2 and CYC1 (top panels) or SYP (bottom panels). 
Dark horizontal lines represent the median, with the box representing the 25th and 75th percentiles, 
the whiskers the 5th and 95th percentiles. For each mRNA, the average of control values was set to 1 
and all values were calculated relatively. * p<0.05 ** p<0.01, Student’s t-test 
 
Fig. 7 
Correlation between miRNA and CDK5R1 expression. Correlation analysis between each miR-103, 
miR-107, miR-15a, miR-15b, miR-16 and miR-195 and CDK5R1 normalized on SYP in 
hippocampus samples of AD patients (blue diamonds) and controls (red diamonds). r = Pearson's 
correlation coefficient 
 
Fig. S1 
miRNA sensors validation. a Luciferase activity of miRNA sensor constructs in SK-N-BE cells 
normalised on pmirGLO- empty vector. b Luciferase activity of representative miRNA sensors with 
a sequence perfectly complementary to the endogenous miRNA (wt) or with a 4-bases mutation in 
the seed sequence (mut). c Luciferase activity of sensor constructs cotransfected with 5 nM of the 
specific miRNA antisense LNA molecule.  * p<0.05 ** p<0.01, Student’s t-test 
 
Fig. S2 
Levels of miR-15/107 miRNAs expression in AD and control brain tissues. The expression levels of 
miR-15/107 miRNAs in three different brain areas (temporal cortex, hippocampus and cerebellum) 
32 
 
of AD patients (n= 12) and controls (n= 12) are represented as relative expression to the small 
nucleolar RNA RNU6B 
 
Fig. S3 
Levels of CDK5R1 and BACE1 expression in AD and control brain tissues. The expression levels 
of CDK5R1 and BACE1 genes in three different brain areas (temporal cortex, hippocampus and 
cerebellum) of AD patients (n= 12) and controls (n= 12) are represented as relative expression to 
the SYP gene. * p<0.05, Student’s t-test 
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